SI3268385T1 - Kombinirana T-celična receptorska genska terapija raka proti na MHC I in MHC II omejenim epitopom tumorskega antigena NY-ESO-1 - Google Patents
Kombinirana T-celična receptorska genska terapija raka proti na MHC I in MHC II omejenim epitopom tumorskega antigena NY-ESO-1Info
- Publication number
- SI3268385T1 SI3268385T1 SI201630678T SI201630678T SI3268385T1 SI 3268385 T1 SI3268385 T1 SI 3268385T1 SI 201630678 T SI201630678 T SI 201630678T SI 201630678 T SI201630678 T SI 201630678T SI 3268385 T1 SI3268385 T1 SI 3268385T1
- Authority
- SI
- Slovenia
- Prior art keywords
- mhc
- eso
- combined
- gene therapy
- cell receptor
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 2
- 108700042075 T-Cell Receptor Genes Proteins 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000001415 gene therapy Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Environmental Sciences (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15159001.5A EP3067366A1 (en) | 2015-03-13 | 2015-03-13 | Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1 |
| EP16712262.1A EP3268385B1 (en) | 2015-03-13 | 2016-03-11 | Combined t cell receptor gene therapy of cancer against mhc i and mhc ii-restricted epitopes of the tumor antigen ny-eso-1 |
| PCT/EP2016/055242 WO2016146505A1 (en) | 2015-03-13 | 2016-03-11 | Combined t cell receptor gene therapy of cancer against mhc i and mhc ii-restricted epitopes of the tumor antigen ny-eso-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3268385T1 true SI3268385T1 (sl) | 2020-07-31 |
Family
ID=52669528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201630678T SI3268385T1 (sl) | 2015-03-13 | 2016-03-11 | Kombinirana T-celična receptorska genska terapija raka proti na MHC I in MHC II omejenim epitopom tumorskega antigena NY-ESO-1 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10781243B2 (enExample) |
| EP (3) | EP3067366A1 (enExample) |
| JP (2) | JP6998211B2 (enExample) |
| CN (2) | CN114195883A (enExample) |
| AU (1) | AU2016232441B2 (enExample) |
| CA (1) | CA2974955A1 (enExample) |
| DK (1) | DK3268385T3 (enExample) |
| ES (1) | ES2784315T3 (enExample) |
| HU (1) | HUE049444T2 (enExample) |
| PL (1) | PL3268385T3 (enExample) |
| PT (1) | PT3268385T (enExample) |
| SI (1) | SI3268385T1 (enExample) |
| WO (1) | WO2016146505A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9511151B2 (en) | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
| US10988516B2 (en) | 2012-03-26 | 2021-04-27 | Uti Limited Partnership | Methods and compositions for treating inflammation |
| US9603948B2 (en) | 2012-10-11 | 2017-03-28 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
| DK3065771T3 (da) | 2013-11-04 | 2019-06-11 | Uti Lp | Fremgangsmåder og sammensætninger til vedvarende immunterapi |
| KR102859521B1 (ko) | 2015-05-06 | 2025-09-12 | 유티아이 리미티드 파트너쉽 | 지속 치료를 위한 나노입자 조성물 |
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| EP3354658A1 (en) * | 2017-01-25 | 2018-08-01 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Novel t cell receptors and immune therapy using the same for the treatment of cancer and infectious diseases |
| US11236145B2 (en) | 2017-03-23 | 2022-02-01 | Immatics Biotechnologies Gmbh | T cell receptors and immune therapy using the same against PRAME positive cancers |
| SG11201909290TA (en) * | 2017-04-07 | 2019-11-28 | Uti Lp | Assay to measure the potency of receptor-ligand interactions in nanomedicines |
| CN109837245A (zh) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | 一种tcr敲除的靶向ny-eso-1的t细胞受体基因修饰t细胞及其制备方法和应用 |
| CA3083748A1 (en) | 2017-11-29 | 2019-06-06 | Uti Limited Partnership | Methods of treating autoimmune disease |
| ES2983771T3 (es) * | 2018-02-26 | 2024-10-24 | Medigene Immunotherapies Gmbh | TCR de NY-ESO |
| CN110856751B (zh) | 2018-08-24 | 2024-12-03 | 杭州康万达医药科技有限公司 | 包含核酸及tcr修饰的免疫细胞的治疗剂及其应用 |
| EP3760217A1 (en) * | 2019-07-01 | 2021-01-06 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Cd5 specific t cell receptor cell or gene therapy |
| WO2021016109A1 (en) * | 2019-07-19 | 2021-01-28 | The Regents Of The University Of California | T-cell receptors and methods of use thereof |
| CN112390875B (zh) * | 2019-08-16 | 2023-01-24 | 香雪生命科学技术（广东）有限公司 | 一种识别afp的高亲和力t细胞受体 |
| CN113512124A (zh) * | 2020-04-10 | 2021-10-19 | 香雪生命科学技术（广东）有限公司 | 一种识别hpv16的高亲和力tcr |
| CN112501269B (zh) * | 2020-12-15 | 2022-02-18 | 清华大学 | 一种快速鉴定高亲和力tcr抗原交叉反应活性的方法 |
| CN114121142B (zh) * | 2021-09-02 | 2023-10-31 | 四川大学华西医院 | 一种新型基因修饰增强型ny-eso-1特异型tcr-t模型构建方法及应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000060055A1 (en) * | 1999-04-01 | 2000-10-12 | The Brigham And Women's Hospital, Inc. | Modified dendritic cells and uses therefor |
| WO2001055393A2 (en) * | 2000-01-28 | 2001-08-02 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mhc class ii restricted t cell epitopes from the cancer antigen ny-eso-1 |
| AU2002246733B2 (en) * | 2000-12-19 | 2007-09-20 | Altor Bioscience Corporation | Transgenic animals comprising a humanized immune system |
| US20030175250A1 (en) * | 2002-02-13 | 2003-09-18 | Elke Jager | Isolated peptides which bind to HLA molecules and uses thereof |
| GB0411123D0 (en) * | 2004-05-19 | 2004-06-23 | Avidex Ltd | High-affinity NY-ESO T cell receptors |
| US7915036B2 (en) * | 2004-09-13 | 2011-03-29 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compositions comprising T cell receptors and methods of use thereof |
| EP2857508A3 (en) * | 2007-03-05 | 2015-04-15 | International Institute of Cancer Immunology, Inc. | Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of them |
| CN101381402B (zh) * | 2008-10-20 | 2011-06-01 | 中国人民解放军第三军医大学 | Ny-eso-1肿瘤抗原模拟表位及其应用 |
| EP2618835B1 (en) | 2010-09-20 | 2017-07-05 | BioNTech Cell & Gene Therapies GmbH | Antigen-specific t cell receptors and t cell epitopes |
| AU2013266421B2 (en) * | 2012-05-22 | 2017-06-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Murine anti-NY-ESO-1 T cell receptors |
| ES2804538T3 (es) | 2013-01-29 | 2021-02-08 | Max Delbrueck Centrum Fuer Molekulare Medizin Mdc Berlin Buch | Moléculas de unión de alta avidez que reconocen MAGE-A1 |
| RU2578009C2 (ru) * | 2013-05-08 | 2016-03-20 | Закрытое акционерное общество "ЕВРОГЕН" | Способ идентификации нативных пар фрагментов днк или рнк, присутствующих в одних и тех же живых клетках |
| JP6164759B2 (ja) * | 2013-11-21 | 2017-07-19 | Ｒｅｐｅｒｔｏｉｒｅ Ｇｅｎｅｓｉｓ株式会社 | Ｔ細胞受容体およびｂ細胞受容体レパトアの解析システムならびにその治療および診断への利用 |
-
2015
- 2015-03-13 EP EP15159001.5A patent/EP3067366A1/en not_active Withdrawn
-
2016
- 2016-03-11 HU HUE16712262A patent/HUE049444T2/hu unknown
- 2016-03-11 WO PCT/EP2016/055242 patent/WO2016146505A1/en not_active Ceased
- 2016-03-11 PT PT167122621T patent/PT3268385T/pt unknown
- 2016-03-11 EP EP20150462.8A patent/EP3666793A3/en active Pending
- 2016-03-11 EP EP16712262.1A patent/EP3268385B1/en active Active
- 2016-03-11 AU AU2016232441A patent/AU2016232441B2/en active Active
- 2016-03-11 JP JP2017548167A patent/JP6998211B2/ja active Active
- 2016-03-11 SI SI201630678T patent/SI3268385T1/sl unknown
- 2016-03-11 CN CN202111497633.4A patent/CN114195883A/zh active Pending
- 2016-03-11 PL PL16712262T patent/PL3268385T3/pl unknown
- 2016-03-11 CA CA2974955A patent/CA2974955A1/en active Pending
- 2016-03-11 ES ES16712262T patent/ES2784315T3/es active Active
- 2016-03-11 DK DK16712262.1T patent/DK3268385T3/da active
- 2016-03-11 CN CN201680015622.9A patent/CN107428816B/zh active Active
- 2016-03-11 US US15/558,021 patent/US10781243B2/en active Active
-
2021
- 2021-06-15 JP JP2021099266A patent/JP2021151249A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PT3268385T (pt) | 2020-04-08 |
| AU2016232441A1 (en) | 2017-08-10 |
| HUE049444T2 (hu) | 2020-09-28 |
| JP2021151249A (ja) | 2021-09-30 |
| CA2974955A1 (en) | 2016-09-22 |
| EP3067366A1 (en) | 2016-09-14 |
| CN114195883A (zh) | 2022-03-18 |
| EP3666793A2 (en) | 2020-06-17 |
| JP6998211B2 (ja) | 2022-02-04 |
| WO2016146505A1 (en) | 2016-09-22 |
| PL3268385T3 (pl) | 2020-06-29 |
| EP3268385A1 (en) | 2018-01-17 |
| JP2018509163A (ja) | 2018-04-05 |
| US10781243B2 (en) | 2020-09-22 |
| EP3268385B1 (en) | 2020-01-08 |
| US20180057560A1 (en) | 2018-03-01 |
| AU2016232441B2 (en) | 2020-08-27 |
| CN107428816A (zh) | 2017-12-01 |
| HK1247212A1 (en) | 2018-09-21 |
| EP3666793A3 (en) | 2020-07-29 |
| DK3268385T3 (da) | 2020-04-06 |
| ES2784315T3 (es) | 2020-09-24 |
| CN107428816B (zh) | 2022-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE049444T2 (hu) | Rák kombinált T-sejt receptoros génterápiája a NY-ESO-1 tumorantigén MHC I és MHC II által korlátozott epitópjai ellen | |
| IL294982B1 (en) | nk-2 cells and genetically engineered monoclonal antibodies for cancer treatment | |
| IL265759A (en) | Therapeutic and diagnostic methods for cancer | |
| IL271888A (en) | Therapeutic and diagnostic methods for cancer | |
| EP3548048A4 (en) | CANCER IMMUNOTHERAPY WITH CD8 + HIGHLY ENRICHED CHIMERIC ANTIGEN RECEPTOR T CELLS | |
| IL268396A (en) | Diagnostic and therapeutic methods for cancer | |
| IL255372A0 (en) | Therapeutic and diagnostic methods for cancer | |
| HUE061874T2 (hu) | Anti-PD-1 antitestek és besugárzás kombinált alkalmazása a rák kezelésére | |
| IL255312A0 (en) | Therapeutic and diagnostic methods for cancer | |
| HUE059484T2 (hu) | Az NY-ESO-1 tumorantigén - HLA-A | |
| PL3532607T3 (pl) | Restymulacja kriokonserwowanych limfocytów naciekających guza nowotworowego | |
| IL250043A0 (en) | Treatment of cancer using humanized anti-bcma chimeric antigen receptor | |
| EP3206987A4 (en) | Nanoparticles for photodynamic therapy, x-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof | |
| IL254701A0 (en) | Car t-cell therapy directed to lhr for the treatment of solid tumors | |
| IL273071A (en) | Treatment and diagnosis methods for cancer | |
| IL247066A0 (en) | Cancer immunotherapy by combining local and systemic immune stimulation | |
| IL248511A0 (en) | Combined therapy for the treatment of cancer with a focovirus expressing the antigen and a monoclonal antibody against tim-3 | |
| IL262208A (en) | Diagnostic and therapeutic methods for cancer | |
| ZA202102740B (en) | Anti-liv1 immune cell cancer therapy | |
| ZA202102745B (en) | Anti-ptk7 immune cell cancer therapy | |
| EP3271401A4 (en) | Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens | |
| SG11201701035SA (en) | Cancer diagnosis and therapy | |
| IL246607A0 (en) | Improved cellular preparations and methods for cancer treatment | |
| EP3146081A4 (en) | Methods for identifying androgen receptor splice variants in subjects having castration resistant prostate cancer | |
| IL254228B (en) | Cell therapeutic agent for cancer treatment and combination therapy with same |